Key Highlights

  • Net loss was USD 39.1 million for the third quarter of 2026.
  • Cash and cash equivalents were USD 422.8 million at September 30.
  • All 33 patients dosed with TSHA-102 cleared acute safety monitoring.
  • Research and development expenses were USD 28.8 million, up USD 3.1 million.

Taysha Gene Therapies (NASDAQ:TSHA) reported a third-quarter 2026 net loss of USD 39.1 million, against USD 32.7 million a year earlier. Loss per share was USD 0.10, against an estimate of USD 0.13. The company develops TSHA-102, a gene therapy candidate that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.

Clinical Progress for TSHA-102

Management said that, following completion of dosing in both the REVEAL pivotal and ASPIRE trials, all 33 patients dosed with TSHA-102 have cleared the acute post-dosing safety monitoring period associated with AAV gene therapies. Of these, 29 were dosed in the REVEAL Phase 1/2 and pivotal trials and four in the ASPIRE trial. The last pivotal trial patient was dosed over four and a half months before the call, and the last ASPIRE patient over three months before it.

Management said this demonstrates TSHA-102 is well tolerated in all patients. It described the period ahead as including top-line data from the REVEAL pivotal trial six-month interim analysis and potential FDA feedback on the BLA submission pathway in the first half of 2027. Management also referred to a potential nomination of an additional gene therapy candidate in the first half of 2027.

The call included remarks from Dr. Sukumar Nagendran, President and Head of R&D, and from Chief Financial Officer Kamran Alam. Management noted that a Type C meeting with the FDA took place in January 2026.

Operating Expenses and Net Loss

Research and development expenses were USD 28.8 million for the quarter, against USD 25.7 million. The USD 3.1 million increase was driven mainly by higher clinical expenses from the REVEAL Part A Phase 1/2, REVEAL Part B pivotal and ASPIRE trials, along with higher compensation expenses.

General and administrative expenses were USD 13.1 million, against USD 8.3 million. The USD 4.8 million increase was primarily due to higher compensation expenses, including non-cash stock-based compensation, and increases in consulting and professional fees, including commercial launch-readiness initiatives.

For the nine months, Research and Development expenses were USD 101.2 million, against USD 61.5 million. The USD 39.7 million increase was driven mainly by BLA-enabling process performance qualification Manufacturing and higher clinical expenses. General and administrative expenses were USD 34.9 million, against USD 25.0 million, an increase of USD 9.9 million.

Cash and Funding History

Net cash used in Operating Activities for the nine months was USD 114.2 million, mainly from a net loss of USD 128.2 million, partly offset by non-cash adjustments of USD 13.9 million. Those adjustments comprised stock-based compensation of USD 17.4 million and other non-cash items of USD 1.6 million, partly offset by a non-cash net gain on Lease termination of USD 5.1 million.

As of September 30, 2026, the company had cash and cash equivalents of USD 422.8 million, which it believes is sufficient to fund planned operations for at least twelve months from the issuance of the financial statements. It has raised an aggregate of USD 1.19 billion in gross proceeds from equity financings, plus term loans and other sources.

The filing also records the terms of its 2025 Trinity term loans. Prepayment premiums are 3.00% through August 7, 2026, 2.00% from August 8, 2026 through August 7, 2027, and 1.00% after that date until the new Maturity date. The company recorded the loans at a Fair Value of USD 49.8 million at issuance, and incurred USD 1.1 million in Debt issuance costs.

The reported items for the quarter are the net loss of USD 39.1 million, research and development expenses of USD 28.8 million, cash of USD 422.8 million and the clearance of the acute safety window for all dosed patients. The company is listed on the Nasdaq Stock Market.